NAD+: Research Applications

Research Applications

NAD+ research spans aging biology, metabolic disease, neurodegeneration, and cardiovascular health with 15+ clinical trials and extensive preclinical data:

1. Aging and Longevity — Declining NAD+ is a hallmark of aging; supplementation mimics caloric restriction, rejuvenates stem cells, extends healthspan in mice.[3][9]
2. Metabolic Disorders — NMN was studied for muscle insulin-sensitivity endpoints in prediabetic women (Yoshino 2021, Science). NR prevented diet-induced obesity 40% in mice.[10][11]
3. Neurodegenerative Diseases — Alzheimer's (NMN → restored spatial memory), Parkinson's (NADPARK: NR → increased cerebral NAD+, MRS-confirmed), ALS (NR + pterostilbene → improved function).[12][13]
4. Cardiovascular Health — Heart failure, cardiomyopathy, ischemia-reperfusion; NMN restores capillary density/endurance 80% in aged mice (SIRT1-dependent vascular rejuvenation).[14]
5. DNA Repair / Cancer — NAD+ is sole PARP substrate; complex dual role in genomic stability vs tumor metabolism.[1]
6. Immune Modulation — CD38 on macrophages drives M1/M2 polarization; CD38 inhibitors (78c, apigenin) reverse age-related NAD+ decline.[8]
7. Acute Organ Injury — NMN protects against cisplatin-induced AKI (SIRT1-dependent); NAD+ reduced brain infarct volume in rodent ischemia models.[15]
8. Ophthalmology — Photoreceptor survival, retinal degeneration, glaucoma.[2]
9. Fertility — NMN restores oocyte quality, improves ovulation, rescues fertility in aged female mice.[2]
10. CD38 Pathway Pharmacology — Tarragó 2018 (78c CD38 inhibitor in aged mice) and apigenin/luteolin natural CD38 inhibitors used as research tools to dissect CD38-mediated NAD+ decline separate from precursor supplementation.[8]
11. Microbiome-Pharmacokinetic Studies — Christen 2025 head-to-head NMN vs NR vs NAM (n=65) established gut-bacterial NA intermediates as the dominant route of intracellular NAD+ replenishment, reframing precursor-bioavailability research toward microbiome composition.[4]

Comparative Research Context

NAD+ research occupies the intersection of three adjacent fields: mitochondrial biology and bioenergetics, aging and longevity pharmacology, and signaling-enzyme cofactor biochemistry. The signature pharmacology — sirtuin / PARP / CD38 / SARM1 substrate competition with widely different Km values — distinguishes NAD+ from receptor-targeted aging interventions and supports its use as a tool molecule for dissecting how cells partition a finite cofactor pool across competing enzymatic demands. Researchers comparing NAD+ precursor pharmacology with related mitochondrial and longevity peptides commonly cross-reference our MOTS-c, Glutathione, SS-31, and Epithalon pages for parallel mitochondrial-protective, antioxidant, and geroprotector pharmacology. The Mills 2016 long-term mouse study, Yoshino 2021 prediabetic-women trial, Brakedal 2022 NADPARK Parkinson's trial, and Christen 2025 head-to-head precursor study together establish NAD+ pharmacology as one of the best-characterized longevity intervention programs in current research.